CSTL Castle Biosciences, Inc.
Castle Biosciences, Inc. (CSTL) is expected to report earnings on October 29, 2026, after the market close. The consensus earnings estimate is a loss of $0.38 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.0% since its last earnings release on July 30, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Castle Biosciences, Inc.
Castle Biosciences is a commercial-stage dermatologic diagnostics company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions.
Sector
Healthcare
Industry
Medical Labs & Research